Roche’s Tecentriq hits a lung cancer slowdown in its bid to challenge Merck
Roche’s Tecentriq hits a lung cancer slowdown in its bid to challenge Merck
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program
The U.S. Food and Drug Administration (FDA) granted Merck & Co.’s Keytruda another approval, this one in combination with Alimta (pemetrexed) and platinum chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), with … Continue Reading Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program
Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication
The U.S. Food and Drug Administration (FDA) gave Bristol-Myers Squibb’s Opdivo (nivolumab) approval for metastatic small cell lung cancer (SCLC) for patients whose cancer has progressed after platinum-based chemotherapy and at least one other type of … Continue Reading Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication
Top Pharma News of the Week
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover … Continue Reading Top Pharma News of the Week
Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1
In the field of immuno-oncology, the two dominant players are Merck & Company, with Keytruda and Bristol-Myers Squibb Company with Opdivo. PD-1 and PD-L1 are proteins found on cancer cells that allow them … Continue Reading Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1
Merck’s Keytruda shores up head and neck case with first-line trial win
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions. On Wednesday, the New Jersey drugmaker said that … Continue Reading Merck’s Keytruda shores up head and neck case with first-line trial win
Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”
Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current … Continue Reading Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”
Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and chief commercial officer … Continue Reading Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch
FDA Action Alerts: Lannett, Indivior, Insys and Progenics
July can be a notoriously slow period for U.S. Food and Drug Administration (FDA) activity, and this year is no different. There are only five PDUFA dates scheduled for the month, and … Continue Reading FDA Action Alerts: Lannett, Indivior, Insys and Progenics
Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer
Tally another win for Bristol-Myers Squibb’s immunotherapy combination. Wednesday, the New Jersey drugmaker said its Opdivo-Yervoy pairing grabbed an FDA approval in patients with rare colon cancers that have progressed despite other … Continue Reading Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer
Roche eyes next-generation breast cancer crown with Tecentriq’s triple-negative victory
In the immuno-oncology world, all eyes have been on the market battle playing out in the lucrative lung cancer arena. But with its latest data, breast cancer leader Roche is bringing … Continue Reading Roche eyes next-generation breast cancer crown with Tecentriq’s triple-negative victory
Merck’s Keytruda Boosts Response in Hard-to-Treat Lung Cancer
The combination of Merck & Co’s immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said. An early look at results … Continue Reading Merck’s Keytruda Boosts Response in Hard-to-Treat Lung Cancer
Sanofi Plots Cancer Comeback With First New Drug in Years
Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a … Continue Reading Sanofi Plots Cancer Comeback With First New Drug in Years
Merck’s Keytruda continues its string of blockbuster results, but BMS’ Opdivo still leads in sales
At the American Society of Clinical Oncology (ASCO) annual meeting over the weekend, Merck’s Keytruda continued its winning streak. In data presented at the meeting, the cancer immunotherapy was shown … Continue Reading Merck’s Keytruda continues its string of blockbuster results, but BMS’ Opdivo still leads in sales
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual … Continue Reading ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
